Contact Us Locations About Products Pipeline Partnering Patients Investors & News Careers Pipeline Overview Pipeline Overview Rucaparib FAP-2286 Lucitanib Scientific Presentations Clinical Trials Compassionate Use Product Candidates Rucaparib Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. Clovis holds global rights for rucaparib. FAP-2286 and Clovis' Targeted Radionuclide Therapy Development Program FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). FAP-2286 consists of two functional elements; a targeting peptide that binds to FAP and a site that can be used to attach radioactive isotopes for imaging and therapeutic use. The Phase 1/2 LuMIERE study of FAP-2286 is enrolling. FAP is highly expressed in cancer-associated fibroblasts (CAFs) which are found in the majority of cancer types, at varying levels, potentially making it a suitable target across a wide range of tumors. High FAP expression has been shown in multiple tumor types including pancreatic ductal adenocarcinoma, salivary gland, mesothelioma, colon, bladder, sarcoma, squamous NSCLC, and head and neck cancers as well as in cancers of unknown primary. High FAP expression was detected in both primary and metastatic tumor samples and was independent of tumor stage or grade.[i] Clovis holds US and global rights for FAP-2286 excluding Europe, Russia, Turkey, and Israel. FAP-2286 is an unlicensed medical product. Clovis also has global rights to three additional discovery-stage compounds in its Targeted Radionuclide Development Program. For more information about FAP-2286, Targeted Radionuclide Therapy (TRT), or Clovis’ TRT development program CLICK HERE. Lucitanib Lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDFGRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). The LIO-1 Phase 2 study, evaluating lucitanib and nivolumab in gynecologic cancers is underway. Clovis holds global rights for lucitanib excluding China. [i] Kwan T et al. Pan-Cancer Analysis of Fibroblast Activation Protein Alpha (FAP) Expression to Guide Tumor Selection for the Peptide-Targeted Radionuclide Therapy FAP-2286. Virtual Presentation 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2021. CLOVIS-SPONSORED STUDIES Rucaparib PRECLINICAL PHASE I PHASE II PHASE III ATHENA Monotherapy in Ovarian Cancer ATHENA Combination with Nivolumab in Ovarian Cancer TRITON3 Prostate Cancer LODESTAR Solid Tumors with Mutations in HRR Genes FAP-2286 Targeted Radionuclide (Licensed from 3B Pharmaceuticals) PRECLINICAL PHASE I PHASE II PHASE III LuMIERE Solid Tumors Lucitanib PRECLINICAL PHASE I PHASE II PHASE III LIO-1 with Nivolumab in Gynecologic Cancers PARTNER AND RESEARCH INSTITUTION-SPONSORED STUDIES Rucaparib PRECLINICAL PHASE I PHASE II PHASE III CASPAR with Enzalutamide in Prostate Cancer CheckMate 9KD with Nivolumab in Prostate Cancer FRACTION-GC with Nivolumab and Ipilimumab in Gastric Cancer About Pipeline Patients Investors & News Careers Contact Us Privacy Policy Cookie Policy Terms Sitemap COPYRIGHT © 2021 BY CLOVIS ONCOLOGY, ALL RIGHTS RESERVED. By using this website without changing your cookie settings, you agree to our use of cookies. For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. By clicking Accept you consent to our use of cookies. Accept